Organization
Queen's University, Kingston, ON, Canada
2 abstracts
Abstract
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.Org: Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada, University of Western Ontario, London, ON, Canada, Manitoba Prostate Cancer, University of Manitoba, Winnipeg, MB, Canada, CancerCare Manitoba, Winnipeg, MB, Canada, McGill University Health Center, Montreal, QC, Canada, Department of Urology, Dalhousie University, Halifax, NS, Canada, Queen's University, Kingston, ON, Canada, St. Josephs Healthcare, McMaster University, Hamilton, ON, Canada, Northern Alberta Urology Clinic, Edmonton, AB, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Ottawa Hospital, Ottawa, ON, Canada, CIUSSS de l'Estrie – CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, St. Vincent's Hospital Sydney, Sydney, NSW, Australia, Princess Margaret Cancer Centre, University Health Network, Toronto Allergy and Asthma Centre, Oncotelic,
Abstract
A bibliometric analysis of immuno-oncology research: Is a new global leader emerging?Org: Imperial College, London, London, United Kingdom, King's College London, London, United Kingdom, London School of Hygiene and Tropical Medicine, London, United Kingdom, Queen's University, Kingston, ON, Canada, Queen's University Belfast, Belfast, United Kingdom,